Colchicine in acute myocardial infarction: cardiovascular events at 1-year follow up.

ABSTRACT:

Objective

In the COVERT-MI randomised placebo-controlled trial, oral administration of high-dose colchicine at the time of reperfusion and for 5 days in acute ST-elevated myocardial infarction did not reduce infarct size but was associated with a significant increase in left ventricular thrombus (LVT) in comparison to placebo. We aimed to assess the 1-year clinical outcomes of the study population.

Methods

This study is a follow-up analysis of the COVERT-MI study on prespecified secondary clinical endpoints at 1 year. The primary endpoint of this study was a composite of major adverse cardiovascular events (MACEs), including all-cause death, acute coronary syndromes, heart failure events, ischaemic strokes, sustained ventricular arrhythmias and acute kidney injury at 1-year

SUBMITTER: Bouleti C 

PROVIDER: S-EPMC10806482 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature